Fresh Air and β-Blockade
Authors: Paul E. Epstein
Journal: Annals of Internal Medicine (2002)

Editorials5 November 2002Fresh Air and β-BlockadePaul E. Epstein, MD, Deputy EditorPaul E. Epstein, MD, Deputy EditorSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-137-9-200211050-00013 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail In this issue, Salpeter and colleagues (1) present an important meta-analysis on the effects of cardioselective β-blockers in patients with reactive airway disease, a subject they have previously reviewed for the Cochrane Library (2). Their elegant analysis has helped put to rest a question that is both clinically important and controversial: Can cardioselective β-blockers be used safely in patients with recognized obstructive lung disease? The main focus in this meta-analysis is on patients with asthma. The question is clinically important because about 5% of the population of the United States is asthmatic and a substantial number of these patients also ...References1. Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective β-blockers in patients with reactive airway disease: a meta-analysis. Ann Intern Med. 2002;137:715-25. LinkGoogle Scholar2. Salpeter S, Ormiston T, Salpeter E. Cardioselective β-blocker use in patients with reversible airway disease. Cochrane Database Syst Rev. 2001; (2):CD002992. [PMID: 11406056] Google Scholar3. Salpeter S, Ormiston T, Salpeter E. Cardioselective β-blocker use in patients with COPD. Cochrane Database Syst Rev. 2002; [In press]. Google Scholar Author, Article, and Disclosure InformationAuthors: Paul E. Epstein, MD, Deputy EditorAffiliations: Corresponding Author: Customer Service, American College of Physicians–American Society of Internal Medicine, 190 N. Independence Mall West, Philadelphia, PA 19106. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoCardioselective β-Blockers in Patients with Reactive Airway Disease Shelley R. Salpeter , Thomas M. Ormiston , and Edwin E. Salpeter Use of β-Blockers in Patients with Reactive Airway Disease David J. Shulan , Michael Katlan , and Mollie Lavsky-Shulan Use of β-Blockers in Patients with Reactive Airway Disease Shelley R. Salpeter and Thomas M. Ormiston Metrics Cited byCardioselective Beta-Blocker Treatment of Hypertension in Patients with Asthma: When Do Benefits Outweigh Risks?Use of β-Blockers in Patients with Reactive Airway DiseaseDavid J. Shulan, MD, Michael Katlan, MD, and Mollie Lavsky-Shulan, MDCardioselectieve bètablokkers niet gecontraïndiceerd bij astmaCardioselective Beta‐Blockers in Patients with Asthma and Concomitant Heart Failure or History of Myocardial Infarction: When Do Benefits Outweigh Risks? 5 November 2002Volume 137, Issue 9Page: 766-767KeywordsAcute myocardial infarctionAsthmaBronchiDrugsForced expiratory volume in the first second of expirationLibrariesLungsSafetySafety studiesStable coronary artery disease ePublished: 5 November 2002 Issue Published: 5 November 2002 Copyright & PermissionsCopyright © 2002 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...